touchSATELLITE SYMPOSIUM IgG4-related disease: How to identify, diagnose and treat
Watch leading experts discuss the clinical presentation, pathogenesis and diagnosis of immunoglobulin G4-related disease (IgG4-RD), and review current and emerging treatment strategies.
Prof. John Stone
Harvard Medical School and Massachusetts General Hospital, Boston, MA, USA
CHAIR
Panelists:
Prof. John Stone introduces this touchSATELLITE SYMPOSIUM on how to identify, diagnose and treat IgG4-RD that was recorded at the ACR Convergence 2023.
Prof. John Stone discusses the pathophysiology of IgG4-RD and reviews the clinical presentation and typical organ involvement of this rare immune-mediated condition.
Tutorial
These icons indicate there is something to be interacted with. Click it when you see it.
The faculty answer questions submitted by the live audience.
Dr Emanuel Della Torre reviews the American College of Rheumatology and European League Against Rheumatism IgG4-RD classification criteria, as well as the Japanese revised comprehensive diagnostic criteria.
Tutorial
These icons indicate there is something to be interacted with. Click it when you see it.
The faculty answer questions submitted by the live audience.
Dr Arezou Khosroshahi reviews current treatment strategies for IgG4-RD, as well as novel targeted agents in clinical development.
Tutorial
These icons indicate there is something to be interacted with. Click it when you see it.
The faculty answer questions submitted by the live audience.
In this session, the panellists review an illustrative patient case and provide their expert perspectives on the identification and diagnosis of IgG4-RD; followed by key learnings from the symposium.
Tutorial
These icons indicate there is something to be interacted with. Click it when you see it.
Overview & Learning Objectives
Overview
In this activity, leading rheumatologists come together during the American College of Rheumatology (ACR) Convergence 2023 to examine the clinical presentation of immunoglobulin G4-related disease (IgG4-RD) and typical organ involvement, review diagnostic classification criteria and current treatment options, and consider how emerging targeted therapies may impact future practice. The expert panel goes on to discuss a patient case that incorporates diagnostic and treatment strategies into clinical practice to facilitate early disease management.
This activity is jointly provided by USF Health and touchIME. read more
Target Audience
This activity has been designed to meet the educational needs of rheumatologists involved in the management of IgG4-RD.
Disclosures
Faculty
Prof. John Stone discloses:Â Advisory board or panel fees from Amgen, Horizon Therapeutics, IQVIA and Novartis. Consultancy fees from AbbVie, Amgen, Argenx, Bristol Myers Squibb, Connect Biopharma, Genentech, Horizon Therapeutics, IQVIA, Novartis, PPD, Prometheus Biosciences, Q32 Bio, Quell Therapeutics, Sanofi and Zenas BioPharma. Grants/research support from AbbVie, Amgen, Argenx, Bristol Myers Squibb, Connect Biopharma, Genentech, Horizon Therapeutics, IQVIA, Novartis, PPD, Prometheus Biosciences, Q32 Bio, Quell Therapeutics, Sanofi and Zenas BioPharma.
Dr Emanuel Della Torre discloses: Advisory board or panel fees from Horizon Therapeutics and Zenas BioPharma. Consultancy fees from Bristol Myers Squibb, Horizon Therapeutics, Roche, Sanofi and Zenas BioPharma (relationships terminated).
Dr Arezou Khosroshahi discloses: Advisory board or panel fees from Horizon Therapeutics. Grants/research support from Pfizer (relationship terminated).
Content reviewer
Loutfi Succari, MD, has no financial interests/relationships or affiliations in relation to this activity.
Touch Medical Directors
Katrina Lester and Kathy Day have no financial interests/relationships or affiliations in relation to this activity.
USF Health Office of Continuing Professional Development and touchIME staff have no financial interests/relationships or affiliations in relation to this activity.
Requirements for Successful Completion
In order to receive credit for this activity, participants must review the content and complete the post-test and evaluation form. Statements of credit are awarded upon successful completion of the post-test and evaluation form.
If you have questions regarding credit please contact cpdsupport@usf.edu.
Accreditations
Physicians
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through a joint providership of USF Health and touchIME. USF Health is accredited by the ACCME to provide continuing medical education for physicians.
USF Health designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Advanced Practice Providers
Physician Assistants may claim a maximum of 1.0 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 CreditTMÂ from organizations accredited by ACCME or a recognized state medical society.
The AANPCP accepts certificates of participation for educational activities approved for AMA PRA Category 1 CreditTMÂ by ACCME-accredited providers. APRNs who participate will receive a certificate of completion commensurate with the extent of their participation.
Date of original release: 12 December 2023. Date credits expire: 12 December 2024.
If you have any questions regarding credit please contact cpdsupport@usf.edu.
Learning Objectives
After watching this activity, participants should be better able to:
- Describe the complex pathophysiology and clinical manifestations of IgG4-RD
- Outline the diagnostic and classification criteria for IgG4-RD
- Discuss current treatments for IgG4-RD as well as novel, emerging targeted treatment options
Faculty & Disclosures
Prof. John Stone
Harvard Medical School and Massachusetts General Hospital, Boston, MA, USA
Prof. John Stone is professor of medicine and Edward A Fox Chair in Medicine at Massachusetts General Hospital (MGH), Boston, MA, USA. read more
He received his medical degree from Harvard Medical School and has been in practice for more than 20 years.Â
Prof. Stone’s long-standing interests are in clinical and translational scientific research in rheumatic diseases. His work has focused on systemic vasculitides and, more recently, on immunoglobulin G4-related disease (IgG4-RD) and glucocorticoid toxicity.Â
Prof. Stone has led a number of important clinical trials in vasculitis, including the WGET, RAVE and GiACTA trials. This work led to regulatory drug approvals of rituximab for anti-neutrophil cytoplasmic antibody-associated vasculitis and tocilizumab for giant cell arteritis and Takayasu’s arteritis. The data for all three of these trials were published in The New England Journal of Medicine.Â
Prof. Stone’s group at MGH has identified several new disease associations with IgG4-RD, including lymphoplasmacytic thoracic aortitis, eosinophilic angiocentric fibrosis and Riedel’s thyroiditis. He is the principal investigator of several trials in this area.Â
Additionally, in the last couple of years, Prof. Stone’s research has focused on the measurement and prevention of glucocorticoid toxicity. This led to the development of a Glucocorticoid Toxicity Index, designed as an outcome measure for clinical trials. He is also a co-founder of a company called Steritas, which helps to reduce the world’s dependence on glucocorticoids.
Prof. John Stone discloses: Advisory board or panel fees from Amgen, Horizon Therapeutics, IQVIA and Novartis. Consultancy fees from AbbVie, Amgen, Argenx, Bristol Myers Squibb, Connect Biopharma, Genentech, Horizon Therapeutics, IQVIA, Novartis, PPD, Prometheus Biosciences, Q32 Bio, Quell Therapeutics, Sanofi and Zenas BioPharma. Grants/research support from AbbVie, Amgen, Argenx, Bristol Myers Squibb, Connect Biopharma, Genentech, Horizon Therapeutics, IQVIA, Novartis, PPD, Prometheus Biosciences, Q32 Bio, Quell Therapeutics, Sanofi and Zenas BioPharma.
Dr Emanuel Della Torre
Vita-Salute San Raffaele University and San Raffaele Hospital, Milan, Italy
Dr Emanuel Della Torre is assistant professor of rheumatology at Vita-Salute San Raffaele University and senior consultant at the Unit of Immunology, Rheumatology, Allergy, and Rare Disease of San Raffaele Hospital in Milan, Italy. read more
After receiving his medical degree and board certification in allergy and clinical immunology, and PhD in basic and applied immunology, Dr Della Torre completed his post-doc in the US at the Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard, in Boston, MA. Dr Della Torre returned to Italy in 2018 and established his laboratory within the Division of Genetic and Cell Biology of the San Raffaele Hospital in Milan.Â
With his seminal works, Dr Della Torre has contributed to the characterization of immunoglobulin G4-related disease and is currently considered a world expert in this area.
Dr Emanuel Della Torre discloses: Advisory board or panel fees from Horizon Therapeutics and Zenas BioPharma. Consultancy fees from Bristol Myers Squibb, Horizon Therapeutics, Roche, Sanofi and Zenas BioPharma (relationships terminated).
Dr Arezou Khosroshahi
Emory University School of Medicine, Atlanta, GA, USA
Dr Arezou Khosroshahi is associate professor of medicine and director of clinical trial research at the Division of Rheumatology at the Emory University School of Medicine in Atlanta, GA, USA. read more
She received her medical degree from Tehran University Medical School in Iran and completed her residency at St. Luke’s–Roosevelt Hospital Center in New York, NY, USA. After completing her rheumatology fellowship at Massachusetts General Hospital, Harvard Medical School, she became involved in clinical research.Â
Dr Khosroshahi’s main interest is in improving and advancing therapies for autoimmune diseases. She is the director of clinical trials at Emory Rheumatology. Her efforts to understand different aspects of immunoglobulin G4-related disease (IgG4-RD) over the past 10 years have led to important findings, including adding new clinical manifestations to the list of organs involved with this protean disease and its responsiveness to B-cell depletion. She co-directed the first two international symposia on IgG4-RD to bring together investigators from all around the world, and helped to establish the name of the disease, pathology statements for diagnosis and management guidelines. She is currently an active member of an international committee for the development of classification criteria and validation of the IgG4-RD Responder Index.
Dr Arezou Khosroshahi discloses: Advisory board or panel fees from Horizon Therapeutics. Grants/research support from Pfizer (relationship terminated).
REGISTER NOW FOR FREE ACCESS TO
- 1000+ topical and insightful peer-reviewed journal articles
- 100+ hours of bite-sized congress highlights
- 8 major therapy areas packed with the latest scientific advances
- 150+ specialties offering learn-on-the-go medical education
- + Concise email updates and newsletters so you never miss out
